UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, ~~2023~~2024

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-37467

Astria Therapeutics, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware		26-3687168
(State or Other Jurisdiction of Incorporation or Organization)		(IRS Employer Identification No.)

75 State Street Suite 1400
Boston, Massachusetts		02109
(Address of Principal Executive Offices)		(Zip Code)

(617) 349-1971

(Registrant’s Telephone Number, Including Area Code)

Securities Registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		ATXS		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of April ~~28, 2023,~~30, 2024, there were ~~28,025,844~~54,913,061 shares of the registrant’s common stock, par value $0.001 per share, outstanding.

Table of Contents

TABLE OF CONTENTS


		Page
PART I. FINANCIAL INFORMATION		35
Item 1.	Financial Statements (unaudited)	35
	Condensed Consolidated Balance Sheets as of March 31, ~~2023~~2024 and December 31, ~~2022~~2023	35
	Condensed Consolidated Statements of Operations for the three months ended March 31, ~~2023~~2024 and ~~2022~~2023	46
	Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, ~~2023~~2024 and ~~2022~~2023	57
	Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity for the three months ended March 31, ~~2023~~2024 and ~~2022~~2023	68
	Condensed Consolidated Statements of Cash Flows for the three months ended March 31, ~~2023~~2024 and ~~2022~~2023	810
	Notes to Condensed Consolidated Financial Statements	911
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	1719
Item 4.	Controls and Procedures	24
		28
PART II. OTHER INFORMATION		2529
Item 1A.	Risk Factors	2529
Item 5.	Other Information	29
Item 6.	Exhibits	2530

SIGNATURES		2631

Table of Contents

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA

This Quarterly Report on Form 10-Q contains forward-looking statements, which reflect our current views with respect to, among other things, our operations and financial performance, strategy, future financial condition and clinical and preclinical development programs. Such forward-looking statements are subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. All statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, clinical and preclinical development programs, regulatory filings and expected market growth are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

These forward-looking statements include, among other things, statements about:

●

our expectations regarding the potential significance of the ~~preliminary~~ results from the Phase 1a ~~STAR-0215~~ clinical trial ~~and the anticipated nature and timing~~ of ~~receipt of the data from additional cohorts in such trial;~~STAR-0215;

●

our expectations regarding the ~~timing, nature, goals and~~potential significance of the initial results ~~of our~~from the ALPHA-STAR Phase 1b/2 clinical trial of STAR-0215, ~~and~~including our expectation that ~~favorable~~the results from such trial could allow us to move directly into a Phase 3 pivotal trial of STAR-0215 as a potential treatment for hereditary angioedema, or ~~HAE;~~HAE, immediately followed by a second Phase 3 trial to support label expansion to dosing every six months;

●

our expectations regarding the timing of reporting additional data from the ALPHA-STAR trial and reporting initial safety and efficacy data from the ALPHA-SOLAR long-term open-label trial of STAR-0215;

●

our expectations about the design and anticipated timing of a Phase 3 pivotal ~~clinical~~ trial for STAR-0215 as a potential treatment for HAE ~~assuming positive data from the~~and a second Phase ~~1b/2 trial;~~3 trial to support label expansion to dosing every six months;

●

our expectations about the unmet medical need for HAE, the potential differentiating attributes of STAR-0215 as a potential treatment for HAE, along with the potential market impact of such differentiation, the potential of STAR-0215 to be a best-in-class monoclonal antibody inhibitor of plasma kallikrein able to provide long-acting, effective attack prevention for HAE, and our vision for STAR-0215 to become the first-choice preventative treatment for HAE with administration every three or six months with the goal of normalizing the lives of people living with HAE;

●

the nature and anticipated growth of the global HAE market and HAE therapies;

●

our plans to ~~improve~~optimize the formulation of STAR-0215 and corresponding work to develop a drug-device combination for STAR-0215 for potential use in late-stage clinical trials and commercially, if approved;

●

our expectations that we have scaled the manufacturing process for STAR-0215 ~~cell line~~ in a manner to generate sufficient material for our planned STAR-0215 nonclinical and clinical studies;

●

the potential therapeutic benefits and potential attributes of STAR-0310, a preclinical stage product candidate which we licensed in October 2023, and our plans to develop STAR-0310 as a treatment for atopic dermatitis, or AD;

●

our expectations regarding the timing of regulatory submissions for STAR-0310;

●

our expectations about the design and anticipated timing of planned clinical trials of STAR-0310;

●

our expectations regarding the timing and nature of anticipated data for planned clinical trials of STAR-0310;

Table of Contents

●

the potential commercial opportunity for STAR-0310 in AD and the likelihood that it can effectively compete in AD, assuming it is approved;

●

the estimated size and anticipated growth of the AD market and the need for treatments for AD;

●

the potential to pursue the development of STAR-0310 in additional indications;

●

our goals and visions for the STAR-0310 program;

●

our expectations regarding our ability to expand our pipeline;

●

the potential benefits of any future acquisition, in-license, collaboration or preclinical development activities;

●

our manufacturing plans, capabilities and strategy;

●

our intellectual property position and strategy;

●

our estimates regarding our cash runway, expenses, future revenue, capital requirements and needs for additional financing, including additional financing to fund our long-term operations;

●

developments relating to our competitors and our industry; and

●

the impact of government laws and regulations.

~~Table of Contents~~

We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2022,~~2023, particularly in the sections entitled “Summary of the Material Risks Associated with Our Business” and “Risk Factors”, that could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures or investments that we may make or enter into.

Table of Contents

PART I- FINANCIAL INFORMATION

Item 1. Financial Statements

Astria Therapeutics, Inc.

Condensed Consolidated Balance Sheets

(In thousands, except share and per share data)

(Unaudited)

��

March 31,

December 31,

2023

2022
Assets

Current assets:

Cash and cash equivalents

$
202,301

$
20,525
Short-term investments

11,027

205,912
Prepaid expenses and other current assets

2,117

1,253
Total current assets

215,445

227,690
Right-of-use asset

806

948
Other assets

1,989

1,995
Total assets

$
218,240

$
230,633
Liabilities and stockholders’ equity

Current liabilities:

Accounts payable

$
930

$
788
Accrued expenses

5,156

7,690
Current portion of operating lease liabilities

587

582
Total current liabilities

6,673

9,060
Long term portion of operating lease liabilities

207

357
Total liabilities

6,880

9,417
Commitments (Note 6)

Stockholders’ equity:

Preferred stock, $0.001 par value per share, 4,908,620 shares authorized and no shares issued and outstanding

—

—
Series X redeemable convertible preferred stock, $0.001 par value per share, 91,380 shares authorized; 31,107 and 31,455 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively

95,324

96,398
Common stock, $0.001 par value per share, 150,000,000 shares authorized; 27,986,718 and 27,501,340 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively

28

28
Additional paid-in capital

634,843

632,512
Accumulated other comprehensive loss

(4)

(79)
Accumulated deficit

(518,831)

(507,643)
Total stockholders’ equity

211,360

221,216
Total liabilities and stockholders’ equity

$
218,240

$
230,633


	March 31,		December 31,
	2024		2023
Assets
Current assets:
Cash and cash equivalents	$	172,012	$	175,530
Short-term investments		197,895		71,000
Prepaid expenses and other current assets		4,614		4,412
Total current assets		374,521		250,942
Right-of-use asset		210		363
Other assets		4,076		3,361
Total assets	$	378,807	$	254,666
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	862	$	1,513
Accrued expenses		10,042		9,708
Current portion of operating lease liabilities		168		329
Total current liabilities		11,072		11,550
Total liabilities		11,072		11,550
Commitments (Note 6)
Stockholders’ equity:
Preferred stock, $0.001 par value per share, 4,908,620 shares authorized and no shares issued and outstanding		—		—
Series X redeemable convertible preferred stock, $0.001 par value per share, 91,380 shares authorized; 31,107 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively		95,324		95,324
Common stock, $0.001 par value per share, 150,000,000 shares authorized; 54,903,061 and 41,034,797 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively		55		41
Additional paid-in capital		872,832		728,285
Accumulated other comprehensive loss		(14)		—
Accumulated deficit		(600,462)		(580,534)
Total stockholders’ equity		367,735		243,116
Total liabilities and stockholders’ equity	$	378,807	$	254,666

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

Astria Therapeutics, Inc.

Condensed Consolidated Statements of Operations

(In thousands, except share and per share data)

(Unaudited)


	Three Months Ended March 31,				Three Months Ended March 31,
	2023		2022		2024		2023
Operating expenses:
Research and development	$	8,033	$	10,358	$	15,726	$	8,033
General and administrative		5,460		5,020		8,424		5,460
Total operating expenses		13,493		15,378		24,150		13,493
Loss from operations		(13,493)		(15,378)		(24,150)		(13,493)
Other income (expense):
Interest and investment income		2,321		56		4,241		2,321
Other expense, net		(16)		(1)		(19)		(16)
Total other income, net		2,305		55		4,222		2,305
Net loss		(11,188)		(15,323)		(19,928)		(11,188)
Net loss per share attributable to common shareholders - basic and diluted	$	(0.40)	$	(1.18)	$	(0.38)	$	(0.40)
Weighted-average common shares outstanding used in net loss per share - basic and diluted		27,944,458		13,016,955		52,294,765		27,944,458

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

Astria Therapeutics, Inc.

Condensed Consolidated Statements of Comprehensive Loss

(In thousands)

(Unaudited)


	Three Months Ended March 31,				Three Months Ended March 31,
	2023		2022		2024		2023
Net loss	$	(11,188)	$	(15,323)	$	(19,928)	$	(11,188)
Other comprehensive gain (loss):
Unrealized gain (loss) on short-term investments, net of tax of $0		75		(53)
Total other comprehensive gain (loss):		75		(53)
Other comprehensive (loss) gain:
Unrealized (loss) gain on short-term investments, net of tax of $0						(14)		75
Total other comprehensive (loss) gain:						(14)		75
Comprehensive loss	$	(11,113)	$	(15,376)	$	(19,942)	$	(11,113)

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

Astria Therapeutics, Inc.

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity

(In thousands, except shares)

(Unaudited)

Series X

Series X

redeemable

redeemable

Accumulated

Total

convertible

convertible

Additional

other

stockholders’

preferred stock,

preferred stock,

Common stock,

Common stock,

paid-in

Accumulated

comprehensive

equity



shares

value

shares

par value

capital

deficit

loss

(deficit)
Balance at December 31, 2022

31,455

$
96,398

27,501,340

$
28

$
632,512

$
(507,643)

$
(79)

$
221,216
Issuance of common stock upon the conversion of preferred stock

(348)

(1,074)

57,910

—

1,074

—

—

—
Issuance of common stock upon exericse of options and warrants

—

—

427,468

—

37

—

—

37
Stock-based compensation expense

—

—

—

—

1,220

—

—

1,220
Unealized gain on short-term investments

—

—

—

—

—

—

75

75
Net loss

—

—

—

—

—

(11,188)

—

(11,188)
Balance at March 31, 2023

31,107

$
95,324

27,986,718

$
28

$
634,843

$
(518,831)

$
(4)

$
211,360


	Series X	Series X
	redeemable	redeemable									Accumulated
	convertible	convertible					Additional				other			Total
	preferred stock,	preferred stock,		Common stock,	Common stock,		paid-in		Accumulated		comprehensive			stockholders’
	shares	value		shares	par value		capital		deficit		loss			equity
Balance at December 31, 2023	31,107	$	95,324	41,034,797	$	41	$	728,285	$	(580,534)	$	—	$	243,116
Issuance of common stock pursuant to an underwriting agreement, net of underwriter’s discount and issuance costs	—		—	10,340,000		10		117,162		—		—		117,172
Issuance of common stock for at-the-market offerings, net of issuance costs	—		—	2,945,806		3		19,999		—		—		20,002
Issuance of common stock upon exercise of options and warrants	—		—	582,458		1		4,632		—		—		4,633
Stock-based compensation expense	—		—	—		—		2,754		—		—		2,754
Unrealized loss on short-term investments	—		—	—		—		—		—		(14)		(14)
Net loss	—		—	—		—		—		(19,928)		—		(19,928)
Balance at March 31, 2024	31,107	$	95,324	54,903,061	$	55	$	872,832	$	(600,462)	$	(14)	$	367,735

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

Astria Therapeutics, Inc.

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity

(In thousands, except shares)

(Unaudited)

Series X

Series X

redeemable

redeemable

Accumulated

Total

convertible

convertible

Additional

other

stockholders’

preferred stock,

preferred stock,

Common stock,

Common stock,

paid-in

Accumulated

comprehensive

equity



shares

value

shares

par value

capital

deficit

loss

(deficit)
Balance at December 31, 2021

31,455

$
96,398

13,016,955

$
13

$
481,709

$
(455,809)

$
—

$
122,311
Expense related to warrants inherited in acquisiton of Quellis

—

—

—

—

1,542

—

—

1,542
Stock-based compensation expense

—

—

—

—

1,209

—

—

1,209
Unrealized loss on short-term investments

—

—

—

—

—

—

(53)

(53)
Net loss

—

—

—

—

—

(15,323)

—

(15,323)
Balance at March 31, 2022

31,455

$
96,398

13,016,955

$
13

$
484,460

$
(471,132)

$
(53)

$
109,686


	Series X	Series X
	redeemable	redeemable									Accumulated			Total
	convertible	convertible					Additional				other			stockholders’
	preferred stock,	preferred stock,		Common stock,	Common stock,		paid-in		Accumulated		comprehensive			equity
	shares	value		shares	par value		capital		deficit		loss			(deficit)
Balance at December 31, 2022	31,455	$	96,398	27,501,340	$	28	$	632,512	$	(507,643)	$	(79)	$	221,216
Issuance of common stock upon the conversion of preferred stock	(348)		(1,074)	57,910		—		1,074		—		—		—
Issuance of common stock upon exercise of options and warrants	—		—	427,468		—		37		—		—		37
Stock-based compensation expense	—		—	—		—		1,220		—		—		1,220
Unrealized gain on short-term investments	—		—	—		—		—		—		75		75
Net loss	—		—	—		—		—		(11,188)		—		(11,188)
Balance at March 31, 2023	31,107	$	95,324	27,986,718	$	28	$	634,843	$	(518,831)	$	(4)	$	211,360

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

Astria Therapeutics, Inc.

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

Three Months Ended March 31,

2023

2022
Operating activities

Net loss

$
(11,188)

$
(15,323)
Reconciliation of net loss to net cash used in operating activities:

Stock-based compensation expense

1,220

1,209
Net gain on warrants inherited in acquisition of Quellis

—

1,542
Right-of-use asset - operating lease

142

—
Other non-cash items

(26)

(79)
Changes in assets and liabilities:

Prepaid expenses and other assets

(864)

163
Lease liability - operating lease

(145)

(15)
Accounts payable

140

(627)
Accrued expenses

(2,532)

571
Net cash used in operating activities

(13,253)

(12,559)
Investing activities

Purchases of short-term investments

(95,923)

(81,702)
Sales and maturities of short-term investments

290,920

54,603
Purchases of property and equipment

(5)

—
Net cash provided by (used in) investing activities

194,992

(27,099)
Financing activities

Proceeds from exercise of stock options

37

—
Net cash provided by financing activities

37

—
Net increase (decrease) in cash, cash equivalents and restricted cash

181,776

(39,658)
Cash, cash equivalents and restricted cash, beginning of period

20,688

86,629
Cash, cash equivalents and restricted cash, end of period

$
202,464

$
46,971
Supplemental disclosure of non-cash transactions:

Conversion of Series X Preferred Stock into common stock

$
1,074

$
—


	Three Months Ended March 31,
	2024		2023
Operating activities
Net loss	$	(19,928)	$	(11,188)
Reconciliation of net loss to net cash used in operating activities:
Stock-based compensation expense		2,754		1,220
Right-of-use asset - operating lease		153		142
Other non-cash items		(665)		(26)
Changes in assets and liabilities:
Prepaid expenses and other assets		(930)		(864)
Lease liability - operating lease		(161)		(145)
Accounts payable		(651)		140
Accrued expenses		334		(2,532)
Net cash used in operating activities		(19,094)		(13,253)
Investing activities
Purchases of short-term investments		(1,049,231)		(95,923)
Sales and maturities of short-term investments		923,000		290,920
Purchases of property and equipment		—		(5)
Net cash (used in) provided by investing activities		(126,231)		194,992
Financing activities
Proceeds from public offering, net of underwriting discounts and issuance costs		117,172		—
Proceeds from at-the-market offering, net of issuance costs		20,002		—
Proceeds from exercise of stock options and warrants		4,633		37
Net cash provided by financing activities		141,807		37
Net (decrease) increase in cash, cash equivalents and restricted cash		(3,518)		181,776
Cash, cash equivalents and restricted cash, beginning of period		175,693		20,688
Cash, cash equivalents and restricted cash, end of period	$	172,175	$	202,464
Supplemental disclosure of non-cash transactions:
Conversion of Series X Preferred Stock into common stock	$	—	$	1,074
Public offering issuance costs in accounts payable and accrued expenses	$	280	$	—

The accompanying notes are an integral part of these condensed consolidated financial statements.

810

Table of Contents

Astria Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1.	Organization and Operations

The Company

Astria Therapeutics, Inc. (the “Company”), ~~formerly known as Catabasis Pharmaceuticals, Inc.,~~ is a biopharmaceutical company focused on the discovery, development and commercialization of novel ~~therapeutics. Its mission is to bring hope with life-changing therapies to patients and families that are affected by rare and niche~~therapeutics for allergic and immunological diseases. On October 26, 2020, the Company announced that the Phase 3 PolarisDMD trial of the Company’s previous lead product candidate, edasalonexent, for the treatment of Duchenne Muscular Dystrophy did not meet its primary and secondary endpoints. Based on these results, the Company announced that it was stopping activities related to the development of edasalonexent, including the Company’s ongoing open-label extension trial. On January 28, 2021, the Company acquired Quellis Biosciences, Inc. (“Quellis”). The Company’s lead product candidate ~~which was acquired in the Quellis acquisition,~~ is STAR-0215, a potential best-in-class monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (“HAE”), a rare, debilitating and potentially life-threatening disease. The Company’s second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis (“AD”), an immune disorder associated with loss of skin barrier function and itching. The Company was incorporated in the State of Delaware on June 26, 2008.

~~Liquidity~~February 2024 Financing

On February 1, 2024, the Company closed an underwritten offering in which the Company sold 10,340,000 shares of common stock at a price of $12.09 per share (the “February 2024 Financing”). The gross proceeds of the February 2024 Financing were $125.0 million and the net proceeds were $117.2 million.

Liquidity

In June ~~30,~~ 2021, the Company entered into an Open Market Sale Agreement^SM with Jefferies LLC ~~("Jefferies"~~(“Jefferies”), pursuant to which the Company ~~can~~could issue and sell shares of common stock ~~of up to $25.0 million~~ under an at-the-market offering program (the ~~“Jefferies~~“2021 ATM Program”). In the three months ended March 31, 2024, the Company sold an aggregate of 2,945,806 shares of common stock under the 2021 ATM Program for gross proceeds of $20.6 million and net proceeds of $20.0 million which completed the sale of all available amounts under the 2021 ATM Program. On March 4, 2024, the Company entered into a new Open Market Sale Agreement^SM with Jefferies, pursuant to which the Company is able to issue and sell up to $150.0 million of shares of common stock under an at-the-market offering program (the “2024 ATM Program” and collectively with the 2021 ATM Program, the “ATM Programs”). The Company pays Jefferies ~~sales agent~~ commissions of up to 3% of the gross proceeds from any common stock sold through the ~~Jefferies~~ ATM Program. On September 15, 2022, the Jefferies ATM Program was modified to increase the amount of the Company’s common stock that may be offered thereunder to an aggregate offering price of up to $50.0 million, with $30.5 million of such amount then being available for future issuance. In November 2022, the Jefferies ATM Program was once again modified to increase the amount of the Company’s common stock that may be offered thereunder to an aggregate offering price of up to $88.1 million, with $50.0 million of such amount then being available for future issuance.Programs. As of March 31, ~~2023, $50.0 million of common stock remains available for sale under~~2024, there has been no activity in the ~~Jefferies~~2024 ATM ~~Program. There~~Program, and there was no activity ~~from~~in the ~~Jefferies~~2021 ATM Program during the three months ended March 31, ~~2023 or 2022.~~2023.

As of March 31, ~~2023,~~2024, the Company had an accumulated deficit of ~~$518.8~~$600.5 million and had available cash, cash equivalents and short-term investments ~~$213.3~~$369.9 million. The Company estimates its existing cash, cash equivalents, and short-term investments are sufficient to sustain operations for at least twelve months from the issuance of these unaudited condensed consolidated financial statements. The Company has been primarily involved with research and development activities and has incurred operating losses and negative cash flows from operations since its inception. The Company anticipates that it will continue to incur significant operating losses for the next several years as it continues to develop its product candidates. The Company has not generated any product revenues and has financed its operations primarily through public offerings and private placements of its equity securities. There can be no assurance that the Company will be able to obtain additional equity, debt ~~equity~~ or other financing or generate product ~~revenues~~revenue or revenues from collaborative partners, on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations, and financial condition.

The Company is subject to a number of risks similar to other life science companies, including, but not limited to, successful discovery and development of its drug candidates, raising additional capital, development by its competitors of new technological innovations, protection of proprietary technology and regulatory approval and market acceptance of the Company’s products. The Company has been primarily involved with research and development activities and has incurred operating losses and negative cash flows from operations since its inception. The Company anticipates that it will continue to incur significant operating losses for the next several years as it continues to develop its product candidates.

911

Table of Contents

2.	Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

The accompanying financial statements and the related disclosures are unaudited and have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”). Additionally, certain information and footnote disclosures normally included in the Company’s annual financial statements have been condensed or omitted from this report. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the financial statements as of and for the year ended December 31, ~~2022~~2023 and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, ~~2022~~2023 (the ~~“2022~~“2023 Annual Report on Form 10-K”).

The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments, including those adjustments that are of a normal and recurring nature, which are necessary to fairly present the Company’s results for the interim periods presented. The results for the three months ended March 31, ~~2023~~2024 are not necessarily indicative of the results for the year ending December 31, ~~2023~~2024 or for any future period.

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Astria Securities Corporation and Quellis Biosciences, LLC, successor in interest to Quellis. All intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. Actual results could differ from such estimates.

The Company utilizes certain estimates to record expenses relating to research and development contracts. These contract estimates, which are primarily related to the length of service of each contract and the amount of service provided as of each measurement date, are determined by the Company based on input from internal project management, as well as from ~~the Company’s~~ service providers.

Net Loss Per Share

Basic net loss per share attributable to common stockholders is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration for common stock equivalents. The Company has included pre-funded warrants to purchase 1,571,093 shares of common stock at an exercise price of $0.001 per share in its computation of weighted average shares outstanding during the period. Diluted net loss per share attributable to common stockholders is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the Company’s dilutive net loss per share attributable to common stockholders calculation, ~~preferred stock,~~ stock options and warrants to purchase the Company’s common ~~stock and preferred~~ stock were considered to be common stock equivalents but were excluded from the calculation of diluted net loss per share attributable to common stockholders, as their effect would be anti-dilutive; therefore, basic and diluted net loss per share attributable to common stockholders were the same for all periods presented.

The following common stock equivalents, including Series X Preferred Stock shown as common stock equivalents, were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:


	Three Months Ended March 31,		Three Months Ended March 31,
	2023	2022	2024	2023
Common stock warrants			6,796,280	1,031,820
Stock options			6,052,298	2,562,234
Series X Preferred Stock	5,184,591	5,242,501	5,184,591	5,184,591
Stock options	2,562,234	1,962,650
Common stock warrants	1,031,820	1,530,176
	8,778,645	8,735,327	18,033,169	8,778,645

Table of Contents

Cash, Cash Equivalents and Restricted Cash

Cash equivalents are short-term, highly liquid investments that are readily convertible into cash, with original maturities of three months or ~~less.~~less and reverse repurchase agreements with a maturity period of one business day at the time of purchase. Cash equivalents are mainly comprised of money market accounts invested in U.S. Treasury securities, corporate debt securities, commercial paper and reverse repurchase ~~agreements.~~

~~Table~~agreements with a maturity period of ~~Contents~~one business day at the time of purchase.

Restricted cash is comprised of deposits with a financial institution used to collateralize letters of credit related to the Company’s lease arrangements. Restricted cash is presented as a component of ~~other long-term assets at March 31, 2023 and~~ prepaid expenses and other current assets ~~and other long-term assets~~ at March 31, ~~2022.~~2024 and other long-term assets at March 31, 2023.

The reconciliation of cash, cash equivalents and restricted cash reported within the applicable condensed consolidated balance sheet that sum to the total of the same such amount shown in the condensed consolidated statement of cash flows is as follows (in thousands):


	March 31,				March 31,
	2023		2022		2024		2023
Cash and cash equivalents	$	202,301	$	46,687	$	172,012	$	202,301
Restricted cash		163		284		163		163
Total	$	202,464	$	46,971	$	172,175	$	202,464

Preferred Stock Discount

In February 2021, the Company issued Series X Preferred Stock in a private placement transaction. It was determined that this transaction resulted in recognition of a beneficial conversion feature, which was valued based on the difference between the price of the shares of common stock on the date of commitment and the conversion price on the closing date, resulting in a total value of $19.6 million. Additionally, the Company incurred total issuance costs of $5.7 million related to the private placement. Both of these features were recorded as a discount on Series X Preferred Stock recognized at the close of the transaction. These features are analogous to preferred dividends and are recorded as a non-cash return to holders of Series X Preferred Stock through additional paid in capital. The discount related to the beneficial conversion feature was recognized through the earliest possible date of conversion, which occurred upon the stockholder approval of the conversion in June 2021. The issuance costs are recognized as a dividend at the time of conversion to common shares. As of March 31, ~~2022,~~2024, $24.4 million of the above amounts were accounted for as a non-cash dividend related to shares of Series X Preferred Stock, and $0.9 million remained to be recognized upon future conversion.

Recent Accounting Pronouncements - Adopted

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies and adopted by the Company as of the specified effective date.

In ~~June 2016, the FASB issued Accounting Standards Update 2016-13,~~ ~~Financial Instruments-Credit Losses~~ (Topic 326). This standard requires a financial asset to be presented at amortized cost basis at the net amount expected to be collected. It also requires that credit losses relating to available-for-sale debt securities should be recorded through an allowance for credit losses. In November 2019, the FASB issued an amendment making this standard effective for annual reporting periods beginning after December 15, 2022 for smaller reporting companies. Early adoption is permitted. The Company adopted this standard on January 1, 2023 with no material impact on the condensed consolidated financial statements.

~~Recent Accounting Pronouncements – Not Yet Adopted~~

In August 2020, the FASB issued Accounting Standards Update 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”), which reduces the number of accounting models for convertible debt instruments and convertible preferred stock as well as amends the derivatives scope exception for contracts in an entity’s own equity. ~~ASU 2020-06 is effective for the~~The Company adopted this standard on January 1, 2024 with ~~early adoption permitted.~~no material impact on the unaudited condensed consolidated financial statements.

In November 2023, the FASB issued Accounting Standards Update 2023-07, Segment Reporting (Topic 280: Improvements to Reportable Segment Disclosures (“ASU 2023-07”). The amendments in this update improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses. The Company adopted this standard on January 1, 2024 with no material impact on the unaudited condensed consolidated financial statements.

Summary of Significant Accounting Policies

The Company’s significant accounting policies are described in Note 2, “Summary of Significant Accounting Policies” in the ~~2022~~2023 Annual Report on Form 10-K, and there were no significant changes to such policies in the three months ended March 31, ~~2023~~2024 that had a material impact on the Company’s results of operations or financial position.

1113

Table of Contents

3.Financial Instruments

The tables below present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of March 31, ~~2023~~2024 and December 31, ~~2022,~~2023, and indicate the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize observable inputs such as quoted prices in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are either directly or indirectly observable, such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs utilize unobservable data points for which there is little or no market data, which require the Company to develop its own assumptions for the asset or liability. There were no transfers between fair value measurement levels during the three months ended March 31, ~~2023~~2024 and ~~2022.~~2023.

The Company’s investment portfolio may include fixed income securities that do not always trade on a daily basis. As a result, the pricing services used by the Company apply other available information as applicable through processes such as benchmark yields, benchmarking of like securities, sector groupings and matrix pricing to prepare valuations. The Company validates the prices provided by its third party pricing services by obtaining market values from other pricing sources and analyzing pricing data in certain instances. The Company also invests in certain reverse repurchase agreements which are collateralized by deposits in the form of U.S. Government Securities and Obligations for an amount no less than 102% of their value. The Company does not record an asset or liability for the collateral as the Company is not permitted to sell or re-pledge the collateral. The collateral has at least the prevailing credit rating of U.S. Government Treasuries and Agencies. The Company utilized a third-party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the reverse repurchase agreements on a daily basis.

The Company accounted for warrants to purchase its stock pursuant to Accounting Standards Codification (“ASC”) Topic 470, Debt, and ASC Topic 480, Distinguishing Liabilities from Equity, and classifies warrants for common stock and preferred stock as liabilities or equity. The warrants classified as liabilities are reported at their estimated fair value and any changes in fair value are reflected in research and development expense. The warrants classified as equity are reported at their estimated fair value with no subsequent remeasurement.

Below is a summary of assets and liabilities measured at fair value on a recurring basis (in thousands):


	As of March 31, 2023								As of March 31, 2024
	Quoted								Quoted
	Prices		Significant		Significant				Prices		Significant		Significant
	in Active		Observable		Unobservable				in Active		Observable		Unobservable
	Markets		Inputs		Inputs				Markets		Inputs		Inputs
	(Level 1)		(Level 2)		(Level 3)		Total		(Level 1)		(Level 2)		(Level 3)		Total
Assets:
Cash equivalents:
Cash and cash equivalents:
Money market funds	$	1,715	$	—	$	—	$	1,715	$	104,705	$	—	$	—	$	104,705
Reverse repurchase agreements		—		69,000		—		69,000
Treasury bills		6,973		—		—		6,973		19,997		—		—		19,997
Short-term investments:
Corporate debt securities		—		6,075		—		6,075
Treasury bills		4,952		—		—		4,952		103,251		—		—		103,251
Reverse repurchase agreements										—		80,000		—		80,000
Treasury notes										14,644		—		—		14,644
Total	$	13,640	$	75,075	$	—	$	88,715	$	242,597	$	80,000	$	—	$	322,597

1214

Table of Contents

As of December 31, 2022

Quoted

Prices

Significant

Significant

in Active

Observable

Unobservable

Markets

Inputs

Inputs


(Level 1)

(Level 2)

(Level 3)

Total
Assets:

Cash and cash equivalents:

Money market funds

$
1,944

$
—

$
—

$
1,944
Short term investments

Corporate debt securities

—

16,445

—

16,445
Yankee securities

—

1,999

—

1,999
Bonds

—

2,988

—

2,988
Treasury bills

5,980

—

—

5,980
Reverse repurchase agreements

—

178,500

—

178,500
Total

$
7,924

$
199,932

$
—

$
207,856


	As of December 31, 2023
	Quoted
	Prices		Significant		Significant
	in Active		Observable		Unobservable
	Markets		Inputs		Inputs
	(Level 1)		(Level 2)		(Level 3)		Total
Assets:
Cash and cash equivalents:
Money market funds	$	7,709	$	—	$	—	$	7,709
Short-term investments:
Reverse repurchase agreements		—		71,000		—		71,000
Total	$	7,709	$	71,000	$	—	$	78,709

The carrying amounts reflected in the unaudited condensed consolidated balance sheets for cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. Items measured at fair value on a recurring basis include cash equivalents and short-term investments as of March 31, ~~2023~~2024 and December 31, ~~2022.~~2023.

4.Short-Term Investments

The following table summarizes the short-term investments held at March 31, ~~2023~~2024 and December 31, ~~2022~~2023 (in thousands):


			Gross Unrealized		Gross Unrealized						Gross Unrealized		Gross Unrealized
	Amortized Cost		Gains		Losses		Fair Value		Amortized Cost		Gains		Losses		Fair Value
March 31, 2023
Corporate debt securities	$	6,082	$	—	$	(7)	$	6,075
March 31, 2024
Treasury bills		4,949		3		—		4,952	$	103,263	$	1	$	(13)	$	103,251
Reverse repurchase agreements										80,000		—		—		80,000
Treasury notes										14,646		—		(2)		14,644
Total	$	11,031	$	3	$	(7)	$	11,027	$	197,909	$	1	$	(15)	$	197,895


			Gross Unrealized		Gross Unrealized						Gross Unrealized		Gross Unrealized
	Amortized Cost		Gains		Losses		Fair Value		Amortized Cost		Gains		Losses		Fair Value
December 31, 2022
Corporate debt securities	$	16,508	$	—	$	(63)	$	16,445
Treasury bills		5,983		—		(3)		5,980
Yankee securities		2,000		—		(1)		1,999
U.S. agency bonds		3,000		—		(12)		2,988
December 31, 2023
Reverse repurchase agreements		178,500		—		—		178,500	$	71,000	$	—	$	—	$	71,000
Total	$	205,991	$	—	$	(79)	$	205,912	$	71,000	$	—	$	—	$	71,000

The contractual maturities of all short-term investments held at March 31, ~~2023~~2024 and December 31, ~~2022~~2023 were one year or less. There were ~~3 and 16~~14 short-term investments in an unrealized loss position with an aggregate ~~values~~value of ~~$6.2 million and $25.6~~$98.2 million as of March 31, ~~2023 and December 31, 2022, respectively.~~2024. These investments were in a loss position for less than 12 months and the Company considered the loss to be temporary in nature. The Company considered the decline in market value for these securities to be primarily attributable to economic and market conditions. ~~As of March 31, 2023, the Company did not intend to sell, and it was not likely that the Company would be required to sell, the investments that~~There were ~~in an unrealized loss position before recovery of their amortized cost basis. Accordingly, the Company did not recognize any other-than-temporary impairments related to its~~no short-term investments in an unrealized loss ~~position.~~

~~Table~~position as of ~~Contents~~December 31, 2023.

Gross realized gains and losses on the sales of short-term investments are included in other income, net. Unrealized holding gains or losses for the period that have been included in accumulated other comprehensive income, as well as gains and losses reclassified out of accumulated other comprehensive income into other income, net, were not material to the Company’s condensed consolidated ~~results~~statements of operations. The cost of investments sold or the amount reclassified out of the accumulated other comprehensive income into other income, net is based on the specific identification method for purposes of recording realized gains and losses. All proceeds in the ~~three-month~~three month periods ended March 31, ~~2023~~2024 and ~~2022~~2023 related to maturities of underlying investments. The gains on proceeds from maturities of short-term investments were not material to the Company’s condensed consolidated ~~results~~statements of operations for the three months ended March 31, ~~2023~~2024 and ~~2022.~~2023.

Table of Contents

5.Accrued Expenses

Accrued expenses consisted of the following (in thousands):


	March 31,		December 31,		March 31,		December 31,
	2023		2022		2024		2023
Accrued contracted costs	$	2,818	$	2,822	$	5,135	$	3,861
Accrued professional fees						2,886		1,485
Accrued compensation		974		3,373		1,638		4,047
Accrued professional fees		955		588
Accrued other		409		407		383		315
Accrued milestones		—		500
Total	$	5,156	$	7,690	$	10,042	$	9,708

6.Commitments

On January 28, 2022, the Company entered into a sublease agreement (the ~~“Sublease”~~“Current Sublease”) with Grant Thornton LLP for new office space to replace its existing office space. The Current Sublease commenced on May 1, 2022 and will end on July 31, 2024 (or on such earlier date as the term may cease or expire as set forth in the Sublease).

Future minimum payments required under the ~~Company’s~~Current Sublease as of March 31, ~~2023~~2024 are summarized as follows (in thousands):


Period Ending December 31,	Amount
2023		446
Period Ending March 31,			Amount
2024		395	$	171
Total lease payments	$	841	$	171
Less: imputed interest		(47)		(3)
Total operating lease liabilities	$	794	$	168

Rent expense was $0.2 million for each of the three months ended March 31, ~~2023~~2024 and ~~2022.~~2023. Lease payments were $0.2 million for each of the three months ended March 31, ~~2023~~2024 and ~~2022.~~2023.

On January 3, 2024, the Company entered into a sublease agreement (the ”New Sublease”) with Duck Creek Technologies LLC for new office space to replace its existing office space. The term of the New Sublease is scheduled to commence on June 1, 2024 and will end on November 30, 2028 (or on such earlier date as the term may sooner cease or expire as set forth in the New Sublease). The New Sublease will increase the future minimum lease payments from approximately $0.2 million to approximately $6.9 million.

7.Stockholders’ Equity

Preferred Stock

Under the Company’s ~~Restated Certificate~~restated certificate of ~~Incorporation,~~incorporation, as amended, the Company has 5,000,000 shares of preferred stock authorized for issuance, with a $0.001 par value per share. Preferred stock may be issued from time to time in one or more series, each series to have such terms as stated or expressed in the resolutions providing for the issue of such series adopted by the ~~Board~~board of ~~Directors~~directors of the Company. Preferred stock which may be redeemed, purchased or acquired by the Company may be reissued except as otherwise provided by law.

As of March 31, 2024, the Company had 31,107 shares of Series X Preferred Stock outstanding. Each share of Series X Preferred Stock is convertible into 166.67 shares of common stock and therefore the number of shares of underlying common stock issuable upon conversion of the Series X Preferred Stock is 5,184,591.

1416

Table of Contents

In January, 2021 the Company into a Stock Purchase Agreement (the “Purchase Agreement”) with certain institutional and accredited investors. Pursuant to the Purchase Agreement, the Company sold an aggregate of 35,573 shares of Series X Preferred Stock for gross proceeds of approximately $110.0 million, and net proceeds of $104.3 million. Each share of Series X Preferred Stock is convertible into 166.67 shares of common stock. On January 3, 2023, a holder of Series X Preferred Stock elected to convert 348 shares of Series X Preferred Stock into 57,910 shares of common stock. As of March 31, 2023, the Company had 31,107 shares of Series X Preferred Stock outstanding and the number of shares of underlying common stock issuable upon conversion of the Series X Preferred Stock was 5,184,591.

Outstanding Warrants

The following table presents information about warrants that are issued and outstanding at March 31, ~~2023:~~2024:


Year Issued	Equity Instrument	Warrants Outstanding	Exercise Price		Date of Expiration	Equity Instrument	Warrants Outstanding	Exercise Price		Date of Expiration
2018	Common Stock	699,962	$	72.00	6/21/2023
2019	Common Stock	331,858	$	37.50	2/7/2024
2023 (1)						Common Stock	6,796,280	$	8.03	10/16/2028
Total		1,031,820					6,796,280
Weighted average exercise price			$	60.90				$	8.03
Weighted average life in years					0.43					4.80

(1) 1,571,093 pre-funded warrants were issued in 2023 and were outstanding as of March 31, 2024, not included in the table above, with an exercise price of $0.001 per share and are exercisable until all pre-funded warrants are exercised in full.

8.Reserved for Future Issuance

The Company has reserved for future issuance the following shares of common stock:


	March 31,	December 31,	March 31,	December 31,
	2023	2022	2024	2023
Warrants for the purchase of common stock			8,367,373	9,271,689
Options outstanding to purchase common stock			6,052,298	3,553,969
Series X Preferred Stock	5,184,591	5,242,501	5,184,591	5,184,591
Options outstanding to purchase common stock	2,562,234	2,253,431
Reserve under the 2015 Stock Incentive Plan and the 2022 Inducement Stock Incentive Plan	1,082,245	1,013,520
Warrants for the purchase of common stock	1,031,820	1,530,176
Reserve under the 2015 Amended and Restated Stock Incentive Plan and the 2022 Inducement Stock Incentive Plan			2,824,689	5,334,301
Shares reserved for the employee stock purchase plan	43,060	36,982	49,139	43,060
Total	9,903,950	10,076,610	22,478,090	23,387,610

9.Stock Incentive Plans

A summary of the Company’s stock option activity and related information follows:


				Weighted						Weighted
				Average	Aggregate					Average	Aggregate
		Weighted-		Remaining	Intrinsic			Weighted-		Remaining	Intrinsic
		Average		Contractual	Value			Average		Contractual	Value
	Shares	Exercise Price		Term (years)	(in thousands)		Shares	Exercise Price		Term (years)	(in thousands)
Outstanding at December 31, 2022	2,253,431	$	15.43	8.57	$	9,733
Outstanding at December 31, 2023							3,553,969	$	13.59	8.39	$	1,912
Granted	474,250	$	13.35				2,622,800	$	15.24
Exercised	(22,472)	$	1.65				(10,000)	$	3.87
Cancelled or forfeited	(142,975)	$	13.52				(113,188)	$	11.07
Outstanding at March 31, 2023	2,562,234	$	15.27	8.57	$	7,370
Vested and exercisable at March 31, 2023	835,970	$	23.94	7.87	$	1,468
Vested and expected to vest at March 31, 2023	2,562,234	$	15.27	8.57	$	7,370
Expired							(1,283)	$	408.60
Outstanding at March 31, 2024							6,052,298	$	14.29	8.80	$	10,660
Vested and exercisable at March 31, 2024							1,501,277	$	16.89	7.46	$	4,062
Vested and expected to vest at March 31, 2024							6,052,298	$	14.29	8.80	$	10,660

The intrinsic value of stock options exercised in the three months ended March 31, 2024 and 2023 was $0.1 million and $0.3 ~~million. There were no stock options exercised in the three months ended March 31, 2022.~~million, respectively. The total grant date fair value of stock options vested for the three months ended March 31, 2024 and 2023 ~~and 2022~~ was ~~$1.5~~$3.2 million and ~~$0.6~~$1.5 million, respectively. The weighted-average grant date fair value per share of options granted ~~to employees and non-employees~~ for the three months ended March 31, 2024 and 2023 was $10.40 and ~~2022 was~~ $8.49, ~~and $4.05,~~ respectively.

~~Table of Contents~~

At March 31, ~~2023,~~2024, the total unrecognized compensation expense related to unvested stock option awards was ~~$11.2~~$37.4 million. The Company expects to recognize that cost over a weighted-average period of approximately ~~2.6~~3.3 years.

~~On February 1, 2023, the Company issued stock options exercisable for 855,000 shares~~17

Table of common stock to certain officers of the Company. Subsequently one officer of the Company left and consequently of these stock options only options exercisable for 755,000 shares remain outstanding. The stock options issued on February 1, 2023 were issued subject to stockholder approval of the authorization of additional shares of common stock for issuance under the Company’s 2015 Amended and Restated Stock Incentive Plan on or before January 31, 2024. Due to this stockholder approval requirement, these stock options are not considered granted as of March 31, 2023. The Company is seeking stockholder approval of an additional 4,300,000 shares for this plan at the Company’s 2023 Annual Meeting of Stockholders, which is scheduled for June 2, 2023. Stockholder approval of this proposal would result in the officer stock option grants discussed above being considered granted.Contents

On February 17, 2022, the Company’s ~~Board~~board of ~~Directors~~directors adopted the 2022 Inducement Stock Incentive Plan (the “Inducement Plan”). The Inducement Plan, as amended, provides for the grant of nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards with respect to an aggregate of ~~300,000~~1,700,000 shares of the Company’s common stock. On January 31, 2023, the Company's Board of Directors approved an amendment to the Inducement Plan to increase the number of shares of common stock authorized for issuance thereunder from 300,000 shares of common stock to 700,000 shares of common stock. Awards under the Inducement Plan may only be granted to persons who (a) were not previously an employee or director of the Company or (b) are commencing employment with the Company following a bona fide period of non-employment, in either case as an inducement material to the individual’s entering into employment with the Company and in accordance with the requirements of Nasdaq Stock Market Rule ~~5635(c)~~5635 (c)(4). As of March 31, ~~2023,~~2024, options to purchase ~~232,800~~688,900 shares of common stock ~~have been granted~~are outstanding under the Inducement Plan, which are included in the table above.

10.Subsequent Events

The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence for certain estimates and to identify matters that require additional disclosure. Subsequent events have been evaluated as required.

1618

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q and the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, ~~2022,~~2023, or the ~~2022~~2023 Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. You should review the sections entitled “Risk Factors” and “Summary of the Material Risks Associated with Our Business” in ~~our 2022~~the 2023 Annual Report on Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. This section provides additional information regarding our business, current developments, results of operations, cash flows, financial condition, contractual commitments and critical accounting policies and estimates that require significant judgement and have the most potential impact on our unaudited condensed consolidated financial statements. This discussion and analysis is intended to better allow investors to view ~~the Company~~our company from management’s perspective.

Overview

We are a biopharmaceutical company focused on the discovery, development and commercialization of novel ~~therapeutics.~~therapeutics for allergic and immunological diseases. Our ~~mission~~focus is to ~~bring hope~~develop first-choice therapies that improve the health and outcomes of patients with ~~life-changing therapies to patients and families that are affected by rare and niche~~ allergic and immunological diseases. Our lead product candidate is STAR-0215, a potential best-in-class monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema, or HAE, a rare, debilitating and potentially life-threatening disease. STAR-0215 has the potential to be the most patient-friendly chronic treatment option for HAE, based on ~~the~~initial proof-of-concept data ~~generated to date~~in HAE patients and the existing HAE treatment landscape. Our second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching. We believe that with both of these programs, we are advancing a pipeline of products with meaningfully differentiated profiles based on validated mechanisms.

STAR-0215

The treatment options for patients with HAE have improved in recent years, however, there is remaining unmet medical need and the global market for HAE therapy is strong and growing. The goal for STAR-0215 is to develop a best-in-class monoclonal antibody inhibitor of plasma kallikrein able to provide long-acting, effective attack prevention for HAE. Our vision for STAR-0215 is to become the first-choice preventative treatment for HAE with administration every three orand six months with the goal of normalizing the lives of people living with HAE. Targeted plasma kallikrein inhibition can prevent HAE attacks by suppressing the pathway that generates bradykinin and causes excessive swelling. STAR-0215 is currently in clinical ~~development. We submitted an investigational new drug application, or IND, for STAR-0215 in June 2022~~development and the U.S. Food and Drug Administration, or FDA, ~~cleared our IND~~has granted Fast Track designation to STAR-0215 for ~~STAR-0215 in July 2022.~~the treatment of HAE.

~~We initiated a Phase 1a clinical trial in August 2022 and~~In February 2023, we announced preliminary results in December 2022. We presented additional initial results from the trial through the first 84 days of follow up at the American Academy of Allergy, Asthma, and Immunology conference in February 2023. This Phase 1a randomized, double-blind, placebo-controlled single ascending dose clinical trial evaluated the safety, pharmacokinetics, or PK, and pharmacodynamics, or PD, of STAR-0215 at a single U.S. center. Healthy subjects received a single dose of STAR-0215 or placebo in three cohorts of 100mg, 300mg, and 600mg administered subcutaneously. STAR-0215 was well-tolerated at all dose levels. Additionally, there were no clinically significant changes in laboratory assessments and there were no treatment-emergent anti-drug antibodies detected. STAR-0215 demonstrated rapid and sustained drug levels with dose-dependent PK and an estimated half-life of up to 117 days. Sustained target engagement was seen with inhibition of plasma kallikrein consistent with levels associated with clinical benefit for at least three months. The initial results from the Phase 1a trial support investigating STAR-0215 in HAE patients and also suggest that there could be an opportunity to dose STAR-0215 less frequently than every three months. As a result, we are evaluating the potential for 6-month dosing with additional healthy subject cohorts in the Phase 1a trial with initial results expected in the fourth quarter of 2023. The final results from the first three cohorts in the Phase 1a trial are also expected in the fourth quarter of 2023.

~~The initial Phase 1a results support STAR-0215’s target profile as a long-acting plasma kallikrein inhibitor and support advancing~~advanced STAR-0215 to a Phase 1b/2 trial called ALPHA-STAR, or A~~stria~~ L~~ong-acting~~ P~~rophylaxis~~Astria Long-acting Prophylaxis for H~~ereditary~~ A~~ngioedema: STAR-0215, which we initiated in February 2023.~~Hereditary Angioedema: STAR-0215. This global, multi-center, open-label, single and multiple dose proof-of-concept clinical trial in people with HAE is evaluating safety, tolerability, HAE attack rate, pharmacokinetics, or PK, pharmacodynamics, or PD, and quality of life in patients three and six months after subcutaneous STAR-0215 administration. We reported initial proof-of-concept data in HAE patients in March 2024, as described below. Target enrollment of 16 patients has been achieved and all doses have been administered. The initial efficacy and safety data-cut was as of March 13, 2024.

Cohort 1 evaluated a 450 mg dose and all four patients had completed 6 months of follow-up. Efficacy observations compared to baseline through 6 months of follow-up were as follows:

●

92% reduction in monthly attack rate

●

96% reduction in moderate and severe attacks

●

91% reduction in acute rescue medication use

●

50% of patients were attack-free through 3 months of follow-up

Table of Contents

Cohort 2 evaluated a 600 mg dose followed by a 300 mg dose three months later, on Day 84. We plan to evaluate this dosing regimen in Phase 3. All six patients had completed 3 months of follow-up and three patients had completed 6 months of follow-up. Efficacy observations compared to baseline through 6 months of follow-up were as follows:

●

96% reduction in monthly attack rate

●

98% reduction in moderate and severe attacks

●

94% reduction in acute rescue medication use

●

67% of patients were attack-free

●

100% of patients were attack-free in the first month after dosing, demonstrating rapid onset of action

Cohort 3 received a 600 mg dose followed by a 600 mg dose one month later, on Day 28. Four of six patients had completed 3 months of follow-up. Efficacy observations compared to baseline through 3 months of follow-up were as follows:

●

90% reduction in monthly attack rate

●

100% reduction in moderate and severe attacks

●

95% reduction in acute rescue medication use

●

50% of patients were attack-free

STAR-0215 was generally well-tolerated with no serious treatment-emergent adverse events, or TEAEs, and no discontinuations. There were two treatment-related TEAEs (both mild), one of which was a case of dizziness and the other a transient injection site reaction (rash). There were no injection site reactions of pain.

We expect to report additional data from ALPHA-STAR in the second half of 2024. We are expanding enrollment in ALPHA-STAR in Cohorts 2 and 3 for a total of up to 28 patients in order to accelerate the collection of data to support potential future approvals.

The observed efficacy, PK, PD, and safety and tolerability profile of STAR-0215 support advancement of STAR-0215 into Phase 3 development. To progress STAR-0215 to market as quickly as possible, we plan to focus the Phase 3 program on every 3-month, or Q3M, dosing initially, immediately followed by a second clinical trial to support label expansion to every 6-month, or Q6M, dosing. Pending regulatory feedback, we expect to start a pivotal Q3M Phase 3 trial in the first quarter of 2025, with top-line results expected by year-end 2026.

We have initiated and are enrolling subjects in ALPHA-SOLAR, a long-term open-label trial assessing the long-term safety and efficacy of STAR-0215. We are currently ~~enrolling~~administering STAR-0215 to those patients ~~in the trial~~who have completed ALPHA-STAR and have ~~initiated administration~~enrolled in ALPHA-SOLAR. Participants are being assigned to receive STAR-0215 in one of ~~STAR-0215 to enrolled patients.~~two dosing regimens: either 300mg Q3M or 600mg Q6M. We expect to report initial safety and efficacy data from ~~single~~ALPHA-SOLAR in mid-2025.

STAR-0310

We believe that OX40 inhibition has the potential to treat AD and ~~multiple dose cohorts~~other diseases. The current treatment options in AD are insufficient to address the ~~trial in mid-2024.~~needs of many patients, and standard of care treatments include steroids and topical medications which can treat symptoms but do not address the underlying disease. Our goal for STAR-0310 is to reduce disease activity, relapse rate, and treatment burden for patients with moderate-to-severe AD. STAR-0310 was engineered with YTE half-life extension technology to enable infrequent dosing. As a potential long-acting OX40 inhibitor, STAR-0310 aims to address the need for a safe, effective, and infrequently administered AD treatment.

1720

Table of Contents

In ~~May 2023,~~2024, we ~~presented~~plan to share preclinical profile results for STAR-0310 and we anticipate submitting an investigational new ~~human mechanistic modeling~~drug application, or IND, to the FDA for STAR-0310 for the treatment of AD by year-end. If the IND clears, we anticipate initiating a Phase 1a clinical trial of STAR-0310 in healthy subjects in the first quarter of 2025 and reporting initial results from the Phase 1a clinical trial in the third quarter of 2025, including PK and PD data atand early signals on safety and tolerability. Assuming positive results from the 13^th ~~C1-Inhibitor Deficiency & Angioedema Workshop. These data support~~Phase 1a clinical trial, we plan to initiate a Phase 1b clinical trial of STAR-0310 in patients with AD in the second half of 2025 and would expect to report results from such trial in the second quarter of 2026. The goals of the Phase 1b trial would be to demonstrate initial efficacy in AD as well as show differentiation in safety and tolerability and the potential for ~~STAR-0215~~a reduced treatment burden as a result of extended half-life as compared to ~~be administered once every three or six months for robust suppression~~existing therapies.

Underwritten Offerings

On October 16, 2023, we closed an underwritten offering of ~~HAE attacks.~~

~~In January 2021,~~(i) 8,253,895 shares of our common stock and accompanying common stock warrants to purchase an aggregate of 6,190,418 shares of common stock and (ii), in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 1,571,093 shares of common stock and accompanying common stock warrants to purchase up to an aggregate of 1,178,320 shares of common stock, which we ~~acquired Quellis Biosciences, Inc., or Quellis, including~~refer to as the ~~STAR-0215 program, and announced a private placement that, upon closing in February 2021, resulted in~~October 2023 Financing. The gross proceeds ~~to us~~ of the October 2023 Financing were approximately ~~$110.0~~$64.0 million ~~before deducting placement agent~~ and ~~other~~net proceeds were $59.5 million.

On February 1, 2024, we closed an underwritten offering ~~expenses,~~of 10,340,000 shares of our common stock, which we refer to as the February ~~2021 Financing.~~

On December 19, 2022, we closed an underwritten public offering of 10,445,050 shares of our common stock, including the full exercise of the underwriters’ option to purchase 1,362,397 shares of our common stock, at a price of $11.01 per share, which we refer to as the December 20222024 Financing. The gross proceeds of the ~~December 2022~~February 2024 Financing were ~~approximately $115.0~~$125.0 million ~~before deducting underwriting discounts~~ and ~~commissions and other offering expenses.~~the net proceeds were $117.2 million.

Financial Overview

Our business is almost entirely dependent on the success of STAR-0215, which is in ~~the early~~ clinical ~~stages of~~ development and has only produced results in a Phase 1a and Phase 1b/2 clinical ~~trial,~~testing and in preclinical and nonclinical ~~settings.~~settings, in addition to STAR-0310, which is in the preclinical stage of development. Our net losses ~~from operations~~ were ~~$13.5~~$19.9 million and ~~$15.4~~$11.2 million for the three months ended March 31, ~~2023~~2024 and ~~2022,~~2023, respectively. As of March 31, ~~2023,~~2024, we had an accumulated deficit of ~~$518.8~~$600.5 million. We have not generated any product revenues and have financed our operations ~~to date~~ primarily through public offerings and private placements of ~~preferred stock before we became a public company,~~ our ~~private placement of preferred stock in the February 2021 Financing and registered offerings of our common stock, including our at-the-market offering programs,~~equity securities and have devoted substantially all of our financial resources and efforts to research and development, including preclinical studies and clinical development programs.

As of March 31, ~~2023,~~2024, we had ~~$213.3~~$369.9 million in cash, cash equivalents and short-term ~~investments. Based on our current operating plan,~~investments, which we expect ~~that our cash, cash equivalents and short-term investments as of March 31, 2023 are sufficient~~will enable us to fund our operating expenses and capital expenditure requirements into mid-2027, including all STAR-0215 program activities through the ~~first half~~completion of ~~2025.~~a planned Q3M Phase 3 pivotal trial as well as advancing our STAR-0310 OX40 program through submission of an IND and early proof-of-concept results from a Phase 1a clinical trial. We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Advancing the development of STAR-0215, STAR-0310, or any future product candidates will require a significant amount of capital. Our existing cash, cash equivalents and short-term investments will not be sufficient to enable us to fund the completion of development of any of our product candidates, including STAR-0215, STAR-0310 or any future product ~~candidates through regulatory approval.~~candidate. We will need to obtain substantial additional funding to complete the development and commercialization of STAR-0215, STAR-0310 or any future product candidates and support our continuing operations, future clinical trials and expansion of our pipeline. Furthermore, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional financing to fund our long-term operations sooner than planned. See the section titled “Liquidity and Capital Resources” below for additional information.

Research and Development Expenses

Research and development expenses consist primarily of costs incurred for our research activities, including our drug discovery efforts, and the development of our product candidates, which include:

●

employee-related expenses including salaries, benefits and stock-based compensation expense;

●

expenses incurred under agreements with third parties, including contract research organizations, or CROs, that conduct clinical trials and research and development and preclinical activities on our behalf;

●

the cost of consultants;

●

the cost of lab supplies and acquiring, developing and manufacturing study and clinical trial materials; and

Table of Contents

●

facilities and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and other supplies.

Research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.

We typically use our employee, consultant and infrastructure resources across our development programs. We track outsourced development costs by product candidate or development program, but we do not allocate personnel costs, other internal costs or external consultant costs to specific product candidates or development programs. We record our research and development expenses net of any research and development tax incentives we are entitled to receive from government authorities.

~~Table of Contents~~

The following table summarizes our research and development expenses by program (in thousands):


	Three Months Ended March 31,				Three Months Ended March 31,
	2023		2022		2024		2023
STAR-0215	$	4,140	$	6,269	$	7,136	$	4,140
STAR-0310						2,975		—
Other programs		710		365		447		710
Costs not directly allocated to programs:
Employee expenses including cash compensation, benefits and stock-based compensation		2,746		1,375		4,141		2,746
Consultants and professional expenses, including stock-based compensation		308		2,226		757		308
Facilities		67		80		95		67
Other		62		43		175		62
Total costs not directly allocated to programs		3,183		3,724		5,168		3,183
Total research and development expenses	$	8,033	$	10,358	$	15,726	$	8,033

We expect to incur significant research and development expenses in the year ending December 31, ~~2023,~~2024, and in future periods in connection with the clinical trials and other activities related to the development of ~~STAR-0215.~~STAR-0215 and the preclinical studies, planned clinical trials and other activities related to the development of STAR-0310. Because of this, we expect that our research and development expenses over the next several quarters will be higher than the prior year periods. Development of STAR-0215, STAR-0310 and any future product candidates is highly uncertain and we cannot reasonably estimate at this time the nature, timing and costs of the efforts that would be necessary to complete the development of any such product candidates. We are also unable to predict when, if ever, material net cash inflows would commence from STAR-0215, STAR-0310 or any other future product candidates. This is due to the fact that we would need to raise substantial additional capital to fund the completion of the clinical development of any such product candidates and the numerous risks and uncertainties associated with developing and commercializing product candidates, including the uncertainties of:

●

establishing an appropriate safety profile with IND-enabling toxicology studies;

●

successful design of, enrollment in, and completion of clinical trials;

●

feedback from the FDA and foreign regulatory authorities on planned trial designs, pre-clinical studies and manufacturing capabilities and plans;

●

changes in the FDA and foreign regulatory approval processes or perspectives that may delay or prevent the approval of new products;

●

receipt of marketing approvals from applicable regulatory authorities;

●

establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;

●

obtaining and maintaining patent and trade secret protection and regulatory exclusivity;

●

launching commercial sales, if we are able to obtain marketing approval, whether alone or in collaboration with others, and our ability to compete successfully with other products; and

●

maintaining a continued acceptable safety profile following approval.

A change in the outcome of any of these variables with respect to the development of STAR-0215, STAR-0310 or any future product candidate, would significantly change the costs and timing associated with the development of that product candidate.

Table of Contents

General and Administrative Expenses

General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in executive, finance, accounting, ~~pre-commercial,~~information technology, new product planning, business development, ~~information technology,~~ legal and human resources functions. Other significant costs include facility costs not otherwise included in research and development expenses, legal fees relating to patent and corporate matters, and fees for accounting and consulting services.

We anticipate that our general and administrative expenses will increase from their current levels as we continue to grow our company, develop STAR-0215 and STAR-0310, and potentially expand our pipeline to include other product candidates.

Other Income, Net

Other income, net consists of interest income earned on our cash, cash equivalents and short-term investments and net amortization expense on short-term investments, and gains and losses related to foreign currency fluctuations.

~~Table of Contents~~

Critical Accounting Estimates

This discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with United States generally accepted accounting principles. We believe that several accounting policies are important to understanding our historical and future performance. We refer to these policies as critical because these specific areas generally require us to make judgments and estimates about matters that are uncertain at the time we make the estimate, and different estimates—which also would have been reasonable—could have been used. On an ongoing basis, we evaluate our estimates and judgments. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

During the three months ended March 31, ~~2023,~~2024, there were no material changes to our critical accounting policies as reported in our ~~2022~~2023 Annual Report on Form 10-K.

Results of Operations

Comparison of the Three Months Ended March 31, ~~2023~~2024 and ~~2022~~2023

The following table summarizes our results of operations for the three months ended March 31, ~~2023~~2024 and ~~2022,~~2023, together with the dollar change in those items (in thousands):


	Three Months Ended March 31,				Period-to-
	2024		2023		Period Change
Operating expenses:
Research and development	$	15,726	$	8,033	$	7,693
General and administrative		8,424		5,460		2,964
Total operating expenses		24,150		13,493		10,657
Loss from operations		(24,150)		(13,493)		(10,657)
Other income, net		4,222		2,305		1,917
Net loss	$	(19,928)	$	(11,188)	$	(8,740)

Three Months Ended March 31,

Period-to-


2023

2022

Period Change
Operating expenses:






Research and development

$
8,033

$
10,358

$
(2,325)
General and administrative

5,460

5,020

440
Total operating expenses

13,493

15,378

(1,885)
Loss from operations

(13,493)

(15,378)

1,885
Other income, net

2,305

55

2,250
Net loss

$
(11,188)

$
(15,323)

$
4,135

Table of Contents

Research and Development Expenses

Research and development expenses ~~decreased~~increased by ~~$2.3~~$7.7 million to $15.7 million for the three months ended March 31, 2024 from $8.0 million for the three months ended March 31, 2023, ~~from $10.4 million for the three months ended March 31, 2022, a decrease~~an increase of ~~22%~~96%. The ~~decrease~~increase in research and development expenses was primarily ~~attributable~~associated with our STAR-0215 program’s advancement in our multi-site international clinical trials in addition to external research and development costs associated with our STAR-0310 program, including manufacturing and IND-enabling activities. These business developments resulted in a $3.0 million increase in CRO and manufacturing expenses to support the ALPHA-STAR and ALPHA-SOLAR clinical trials in addition to a ~~$2.1~~Phase 3 pivotal trial in 2025, a $3.0 million decrease in direct costs to support development of the STAR-0215 program, and a $1.9 million decrease in professional service expenses primarily due to expense recognized on vested warrants in 2022. The decrease in costs to support development of the STAR-0215 program is due to timing of the work performed to submit our IND in the first quarter of 2022, with costs to support clinical operations in the first quarter of 2023 not yet being significant enough to result in an increase in ~~costs~~expenses related to ~~support development of the STAR-0215 program as compared~~external research, manufacturing, and IND-enabling activities related to the ~~first quarter of 2022. These decreases were partially offset by~~STAR-0310 program, a ~~$1.3~~$1.4 million increase in employee expenses, and a ~~$0.4~~$0.5 million increase in ~~costs for~~consulting expenses and other expenses, partially offset by a $0.2 million decrease in expenses attributable to other research programs.

As noted above, we expect that our research and development expenses over the next several quarters will be higher than prior periods. We anticipate initiating a Phase 3 pivotal trial for STAR-0215 in the first quarter of 2025 in addition to submitting an IND to the FDA for STAR-0310 for the treatment of AD by year-end 2024. If the IND clears, we anticipate initiating a Phase 1a clinical trial of STAR-0310 in the first quarter of 2025.

General and Administrative Expenses

General and administrative expenses increased by ~~$0.4~~$2.9 million to $8.4 million for the three months ended March 31, 2024 from $5.5 million for the three months ended March 31, 2023, ~~from $5.0 million for the three months ended March 31, 2022,~~ an increase of 9%54%. The increase in general and administrative expenses was attributable to a ~~$0.3~~$2.0 million increase in ~~employee-related costs~~employee expenses primarily due to stock-based compensation expenses and company growth to support the advancement of our programs, in addition to a ~~$0.3~~$0.9 million increase in professional services ~~expense. These costs were partially offset by a $0.1 million decrease in insurance expense~~due to increased legal fees and ~~a $0.1 million decrease in~~consulting expenses. As noted above, we anticipate that our general ~~office expenses.~~and administrative expenses will increase from their current levels as we continue to grow our company.

~~Table of Contents~~

Other Income, Net

Other income, net increased by ~~$2.3~~$1.9 million to $4.2 million for the three months ended March 31, 2024 from $2.3 million for the three months ended March 31, 2023, ~~from $55 thousand for the three months ended March 31, 2022.~~an increase of 83%. The increase was primarily attributable to an increase in interest and investment income due to higher yields on our interest-earning assets.

Table of Contents

Liquidity and Capital Resources

From our inception through March 31, ~~2023,~~2024, we raised an aggregate of ~~$579.3~~$823.3 million through equity financings including private placements of preferred stock before we became a public company, our private placement of preferred stock in ~~the~~ February 2021 ~~Financing~~ and registered offerings of our common stock, including our at-the-market offering programs.

As of March 31, ~~2023,~~2024, we had ~~$213.3~~$369.9 million in cash, cash equivalents and short-term ~~investments. Based on our current operating plan,~~investments which we expect ~~that our cash, cash equivalents and short-term investments as of March 31, 2023 are sufficient~~will enable us to fund our operating expenses and capital expenditure requirements into mid-2027, including all STAR-0215 program activities through the ~~first half~~completion of ~~2025. Advancing the development~~a planned Q3M Phase 3 pivotal trial, as well as advancing our STAR-0310 OX40 program through submission of ~~STAR-0215~~an IND and ~~other product candidates will require~~early proof-of-concept results from a ~~significant amount of capital. Our existing cash~~Phase 1a trial. We have based this estimate on assumptions that may prove to be wrong, and ~~cash equivalents will not be sufficient to fund any of~~we could use our ~~product candidates through regulatory approval.~~available capital resources sooner than we currently expect. Furthermore, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional financing to fund our long-term operations sooner than planned.

~~We will need to obtain substantial additional funding to complete~~Advancing the development ~~and commercialization~~ of STAR-0215, STAR-0310, or any future product candidates ~~support~~will require a significant amount of capital and our ~~continuing operations, future clinical trials~~existing cash, cash equivalents and short-term investments will not be sufficient to enable us to fund the ~~expansion~~completion of development of any of our ~~pipeline.~~product candidates, including STAR-0215, STAR-0310 or any future product candidate. In addition, STAR-0215, STAR-0310, or any future product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of product candidates that we do not expect to be commercially available for years, if at all. Accordingly, we will need to ~~continue~~obtain substantial additional funding to ~~rely on additional financing to achieve~~complete the development and commercialization of STAR-0215, STAR-0310 or any future product candidates, support our ~~business objectives.~~continuing operations, future clinical trials and the expansion of our pipeline. Adequate additional financing may not be available to us on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of our stockholders. General economic conditions, both inside and outside the United States, including heightened inflation, capital market instability and volatility, interest rate and currency rate fluctuations and economic slowdown or recession as well as ~~the COVID-19 pandemic~~pandemics, epidemics and geopolitical events, including civil or political unrest (such as the Ukraine-Russian ~~war)~~war and the conflict in the Middle East), may have a significant impact on the availability of funding sources and the terms on which any funding may be available. In addition, market instability and volatility, high levels of inflation and interest rate fluctuations may increase our cost of financing or restrict our access to potential sources of future liquidity. If we fail to raise capital as, and when, needed, we may be unable to continue our operations at planned levels and be forced to modify our business strategies and reduce or terminate our operations. Although we will continue to pursue these plans, there is no assurance that we will be successful in obtaining sufficient funding on terms acceptable to us to fund continuing operations when needed or at all.

~~December 2022~~October 2023 Financing

On ~~December 19, 2022,~~October 16, 2023, we closed the October 2023 Financing, in which we sold (i) 8,253,895 shares of our common stock and accompanying common stock warrants to purchase an ~~underwritten public offering~~aggregate of ~~10,445,050~~6,190,418 shares of common stock and (ii), in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 1,571,093 shares of common stock and accompanying common stock warrants to purchase up to an aggregate of 1,178,320 shares of common stock for aggregate gross proceeds of approximately $64.0 million, and net proceeds of $59.5 million.

February 2024 Financing

On February 1, 2024, we closed the February 2024 Financing, in which we sold 10,340,000 shares of our common stock for gross proceeds of ~~approximately $115~~$125.0 million and net proceeds of ~~$107.6~~$117.2 million.

Table of Contents

At-the-Market Offerings

OnIn June ~~30,~~ 2021, we entered into an Open Market Sale Agreement^SM with Jefferies LLC, or Jefferies, pursuant to which we ~~can~~could issue and sell shares of common stock ~~of up to $25.0 million~~ under an at-the-market offering program, or the ~~Jefferies~~2021 ATM Program. In the three months ended March 31, 2024, we sold an aggregate of 2,945,806 shares of common stock under the 2021 ATM Program for gross proceeds of $20.6 million and net proceeds of $20.0 million which completed the sale of all available amounts under the 2021 ATM Program. On March 4, 2024, we entered into a new Open Market Sale Agreement^SM with Jefferies, pursuant to which we are able to issue and sell up to $150.0 million of shares of common stock under an at-the-market offering program, or the 2024 ATM Program, and, collectively with the 2021 ATM Program, the ATM Programs. We pay Jefferies ~~sales agent~~ commissions of up to 3% of the gross proceeds from any common stock sold through the ~~Jefferies~~ ATM Program. On September 15, 2022, the Jefferies ATM Program was modified to increase the amount of our common stock that may be offered thereunder to an aggregate offering price of up to $50.0 million, with $30.5 million of such amount then being available for future issuance. In November 2022, the Jefferies ATM Program was once again modified to increase the amount of our common stock that may be offered thereunder to an aggregate offering price of up to $88.1 million, with $50.0 million of such amount then being available for future issuance.Programs. As of March 31, ~~2023, $50.0 million of common stock remains available for sale under~~2024, there has been no activity in the ~~Jefferies~~2024 ATM ~~Program. There~~Program, and there was no activity ~~from~~in the ~~Jefferies~~2021 ATM Program during the three months ended March 31, ~~2023 and 2022, respectively.~~2023.

~~Table of Contents~~

Cash Flows

Comparison of the Three Months Ended March 31, ~~2023~~2024 and ~~2022~~2023

The following table provides information regarding our cash flows for the three months ended March 31, ~~2023~~2024 and ~~2022~~2023 (in thousands):


	Three Months Ended March 31,				Three Months Ended March 31,
	2023		2022		2024		2023
Net cash used in operating activities	$	(13,253)	$	(12,559)	$	(19,094)	$	(13,253)
Net cash provided by (used in) by investing activities		194,992		(27,099)
Net cash (used in) provided by investing activities						(126,231)		194,992
Net cash provided by financing activities		37		—		141,807		37
Net increase (decrease) in cash, cash equivalents and restricted cash	$	181,776	$	(39,658)
Net (decrease) increase in cash, cash equivalents and restricted cash					$	(3,518)	$	181,776

Net Cash Used in Operating Activities

Net cash used in operating activities was $19.1 million for the three months ended March 31, 2024 and consisted primarily of a net loss of $19.9 million adjusted for stock-based compensation expense of $2.8 million, non-cash items of $0.7 million, an adjustment to our right of use asset of $0.2 million, and a net increase in net assets of $1.5 million, which resulted primarily from an increase in prepaid expenses and long term deposits of $0.9 million, a decrease in accounts payable of $0.7 million, and a decrease in the lease liability of $0.2 million, partially offset by an increase in accrued expenses of $0.3 million.

Net cash used in operating activities was $13.3 million for the three months ended March 31, 2023 and consisted primarily of a net loss of $11.2 million adjusted for stock-based compensation expense of $1.2 million, an adjustment to our right of use asset of $0.1 million, and a net increase in net assets of $3.4 million, which resulted primarily from a decrease in accrued expenses of $2.5 million, an increase in prepaid expenses of $0.9 million and a decrease in the lease liability of $0.1 million, partially offset by an increase in accounts payable of $0.1 million.

Net cash used in operating activities was $12.6 million for the three months ended March 31, 2022 and consisted primarily of a net loss of $15.3 million adjusted for stock-based compensation expense of $1.2 million and expense recognized for warrants of $1.5 million.

Net Cash Provided by (Used in) Investing Activities

Net cash used in investing activities was $126.2 million for the three months ended March 31, 2024 and consisted primarily of purchases of short-term investments of $1.0 billion, partially offset by maturities of short-term investments of $0.9 billion as the proceeds from maturities from short-term investments were reinvested. Net cash provided by investing activities was $195.0 million for the three months ended March 31, 2023 and consisted primarily of maturities of short-term investments of $290.9 million, partially offset by purchases of short-term investments of $95.9 million. Net cash used in investing activities was $27.1 million for the three months ended March 31, 2022 and consisted primarily of proceeds from purchases of short-term investments of $81.7 million, partially offset by maturities of short-term investments of $54.6 million.

Net Cash Provided by Financing Activities

Net cash provided by financing activities was ~~$37 thousand~~$141.8 million for the three months ended March 31, 2024, which was attributable to net proceeds of $117.2 million from the February 2024 Financing, net proceeds of $20.0 million from the 2021 ATM Program and proceeds from exercises of stock options and warrants of $4.6 million. Net cash provided by financing activities was less than $0.1 million for the three months ended March 31, 2023, which was attributable to proceeds from exercises of stock options. ~~There was no cash provided by financing activities for the three months ended March 31, 2022.~~

Table of Contents

Funding Requirements

Our primary uses of capital are for compensation and related expenses, manufacturing costs for preclinical and clinical materials, third party preclinical and clinical research and development services, clinical costs, legal and other regulatory expenses, and general overhead.

As of March 31, ~~2023,~~2024, we had an accumulated deficit of ~~$518.8~~$600.5 million. We have been primarily involved with research and development activities and have incurred operating losses and negative cash flows from operations since our inception.

~~As of March 31, 2023, we had available cash, cash equivalents and short-term investments of $213.3 million.~~ Based on our current operating plan, we expect that our existing cash, cash equivalents and short-term investments ~~as of March 31, 2023 are sufficient~~will enable us to fund our operating expenses and capital ~~expenditures~~expenditure requirements ~~through the first half of 2025.~~

~~Table of Contents~~

into mid-2027. Our estimate as to how long we expect our cash, cash equivalents and short-term investments to be able to fund our operations is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of biotechnology products, we are unable to estimate the exact amount of our operating capital requirements. Further, changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. Our future funding requirements will depend on many factors, including:

●

the progress, timing, costs and results of clinical trials of, and research and preclinical development efforts for STAR-0215, STAR-0310 and any future product candidates, including potential future clinical trials;

●

our ability to enter into and the terms and timing of any collaborations, licensing or other arrangements that we may establish;

●

the number and characteristics of future product candidates that we pursue and their development requirements;

●

the outcome, timing and costs of seeking regulatory approvals;

●

the costs of commercialization activities for any of our product candidates that receive marketing approval to the extent such costs are not the responsibility of any future collaborators, including the costs and timing of establishing product sales, marketing, market access, distribution, supply chain and manufacturing capabilities, and scaling up the manufacturing of drug substance and drug product to clinical and commercial scale and developing a drug device combination, if applicable, securing all raw materials necessary to conduct such scale-up and successfully completing all other activities related thereto;

●

if we obtain marketing approval of any of our product candidates, revenue, if any, received from commercial sales of our product candidates;

●

if we obtain marketing approval of any of our product candidates, our ability to successfully compete against other approved products that are approved or used as treatments for the indications for which our products are approved, including with respect to STAR-0215 in ~~HAE;~~HAE and STAR-0310 in AD;

●

our headcount growth and associated costs;

●

the amount and timing of future milestone and royalty payments potentially payable to Ichnos Sciences SA and Ichnos Sciences Inc., or collectively Ichnos, pursuant to our October 2023 license agreement with Ichnos;

●

the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending against intellectual property related claims;

●

~~the impact of the COVID-19 pandemic on our operations, business and prospects;~~ and

●

the costs of operating as a public company.

Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, STAR-0215, STAR-0310 or any future product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of medicines that we do not expect to be commercially available for years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.

Table of Contents

Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our stockholders’ ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights. Debt financing, if available, would result in periodic payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring debt, making capital expenditures or declaring dividends, that could adversely impact our ability to conduct our business.

If we raise funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

Material Cash Requirements from Known Contractual Obligations

~~Table~~Our material cash requirements from known contractual and other obligations as of ~~Contents~~March 31, 2024 are primarily related to our sublease agreements for office space. For information related to our future commitments relating to our sublease agreement, see Note 6, “Commitments”, of our condensed consolidated financial statements.

We enter into agreements in the normal course of business with CROs for clinical trials and clinical supply manufacturing and with vendors for preclinical research studies and other services and products for operating purposes. The contracts are cancelable at any time by us, generally upon 60 days’ prior written notice to the CRO, and therefore we believe that our non-cancelable obligations under these agreements are not material.

Our license agreement with Ichnos includes potential milestone payments, tiered royalties and other obligations that are dependent upon the development of products using the intellectual property licensed under the agreement and contingent upon the achievement of development or regulatory approval milestones, as well as commercial milestones. These potential obligations are contingent upon future events and the timing and likelihood of such potential obligations are not known with certainty. For further information regarding this agreement, please see Note 1, “Organization and Operations” in our 2023 Annual Report on Form 10-K.

Item 4. Controls and Procedures

Management’s Evaluation of our Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, or the Exchange Act) that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (1) recorded, processed, summarized, and reported within the time periods specified in the U.S. Securities and Exchange Commission’s rules and forms and (2) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our principal executive officer and principal financial officer have concluded based upon the evaluation described above that, as of March 31, ~~2023,~~2024, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

During the three months ended March 31, ~~2023,~~2024, there were no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15(d)-15(f) promulgated under the Exchange Act, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

2428

Table of Contents

PART II – OTHER INFORMATION

Item 1A. Risk Factors

Careful consideration should be given to the factors discussed in Part I, Item 1A, Risk Factors, in our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2022,~~2023, which could materially affect our business, financial condition or future results, in addition to the information set forth in this Quarterly Report on Form 10-Q.

Item 5. Other Information

None of our directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (each as defined in Item 408 of Regulation S-K) during the first quarter of 2024.

Table of Contents

Item 6. Exhibits

The exhibits filed as part of this Quarterly Report on Form 10-Q are set forth on the Exhibits Index below:


Exhibit Number		Exhibit

10.1		~~2022 Inducement Stock Incentive Plan,~~Sublease Agreement, dated as ~~amended~~of January 3, 2024, by and between Duck Creek Technologies LLC and the Registrant (incorporated by reference to Exhibit ~~99.1~~10.19 to the ~~Registrant's Current~~Registrant’s Annual Report on Form ~~8-K~~10-K (File No. 001-37467) filed with the SEC on ~~February 2, 2023)~~March 4, 2024)
31.1*		Certification of principal executive officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*		Certification of principal financial officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**		Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of The Sarbanes-Oxley Act of 2002, by the Registrant’s principal executive officer and principal financial officer
101.INS		Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Presentation Linkbase Document
104		Cover Page Data File (the cover page XBRL tags are embedded within the iXBRL document).

* Filed herewith.

** Furnished herewith.

2530

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Astria Therapeutics, Inc.

Date: May ~~11, 2023~~9, 2024	By:	/s/ NOAH C. CLAUSER
		Noah C. Clauser
		Chief Financial Officer (Principal Financial Officer)

2631

				��
	March 31,		December 31,
	2023		2022
Assets
Current assets:
Cash and cash equivalents	$	202,301	$	20,525
Short-term investments		11,027		205,912
Prepaid expenses and other current assets		2,117		1,253
Total current assets		215,445		227,690
Right-of-use asset		806		948
Other assets		1,989		1,995
Total assets	$	218,240	$	230,633
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	930	$	788
Accrued expenses		5,156		7,690
Current portion of operating lease liabilities		587		582
Total current liabilities		6,673		9,060
Long term portion of operating lease liabilities		207		357
Total liabilities		6,880		9,417
Commitments (Note 6)
Stockholders’ equity:
Preferred stock, $0.001 par value per share, 4,908,620 shares authorized and no shares issued and outstanding		—		—
Series X redeemable convertible preferred stock, $0.001 par value per share, 91,380 shares authorized; 31,107 and 31,455 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively		95,324		96,398
Common stock, $0.001 par value per share, 150,000,000 shares authorized; 27,986,718 and 27,501,340 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively		28		28
Additional paid-in capital		634,843		632,512
Accumulated other comprehensive loss		(4)		(79)
Accumulated deficit		(518,831)		(507,643)
Total stockholders’ equity		211,360		221,216
Total liabilities and stockholders’ equity	$	218,240	$	230,633


	As of December 31, 2022
	Quoted
	Prices		Significant		Significant
	in Active		Observable		Unobservable
	Markets		Inputs		Inputs
	(Level 1)		(Level 2)		(Level 3)		Total
Assets:
Cash and cash equivalents:
Money market funds	$	1,944	$	—	$	—	$	1,944
Short term investments
Corporate debt securities		—		16,445		—		16,445
Yankee securities		—		1,999		—		1,999
Bonds		—		2,988		—		2,988
Treasury bills		5,980		—		—		5,980
Reverse repurchase agreements		—		178,500		—		178,500
Total	$	7,924	$	199,932	$	—	$	207,856